Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neonatal drug therapy: The first frontier of therapeutics for children.

Literature DB >> 26095519

Neonatal drug therapy: The first frontier of therapeutics for children.

K Allegaert^1,2, J van den Anker^3,4,5,6.

Abstract

Knowledge about the safe and effective use of medicines in neonates has increased substantially but has resulted in few label changes. Drugs developed for use in adults are reshaped and tailored to specific neonatal indications. However, the use of drugs in neonates should not only mirror adult pharmacotherapy, but should be driven by their own specific needs. Therefore, building collaborative networks may assist to develop a newborn-driven research agenda addressing their clinical needs and diseases.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2015 PMID： 26095519 PMCID： PMC4709252 DOI： 10.1002/cpt.166

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

61 in total

Review 1. Impact of perinatal corticosteroids on neuromotor development and outcome: review of the literature and new meta-analysis.

Authors: E S Shinwell; S Eventov-Friedman
Journal: Semin Fetal Neonatal Med Date: 2008-12-23 Impact factor: 3.926

2. Adverse drug reactions in neonates and infants: a population-tailored approach is needed.

Authors: Karel Allegaert; Johannes N van den Anker
Journal: Br J Clin Pharmacol Date: 2015-06-01 Impact factor: 4.335

3. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN).

Authors: K De Boeck; V Bulteel; H Tiddens; T Wagner; I Fajac; S Conway; F Dufour; A R Smyth; T Lee; I Sermet; B Kassai; S Elborn
Journal: J Cyst Fibros Date: 2011-06 Impact factor: 5.482

Review 4. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities.

Authors: Evelyne Jacqz-Aigrain
Journal: Early Hum Dev Date: 2011-01-26 Impact factor: 2.079

5. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Authors: Rui Zhu; Jennifer J Kiser; Heiner I Seifart; Cedric J Werely; Charles D Mitchell; David Z D'Argenio; Courtney V Fletcher
Journal: J Clin Pharmacol Date: 2011-05-10 Impact factor: 3.126

Review 6. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.

Authors: R N Hines
Journal: Int J Pharm Date: 2012-07-03 Impact factor: 5.875

7. Covariates of tramadol disposition in the first months of life.

Authors: K Allegaert; J N van den Anker; J N de Hoon; R H N van Schaik; A Debeer; D Tibboel; G Naulaers; B J Anderson
Journal: Br J Anaesth Date: 2008-02-26 Impact factor: 9.166

8. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas.

Authors: M A Turner; J C Duncan; U Shah; T Metsvaht; H Varendi; G Nellis; I Lutsar; S Yakkundi; J C McElnay; H Pandya; H Mulla; P Vaconsin; T Storme; A Rieutord; A J Nunn
Journal: Adv Drug Deliv Rev Date: 2013-11-13 Impact factor: 15.470

9. An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.

Authors: H Mulla; S Yakkundi; J McElnay; I Lutsar; T Metsvaht; H Varendi; G Nellis; A Nunn; J Duncan; H Pandya; M Turner
Journal: Pharm Res Date: 2014-09-19 Impact factor: 4.200

10. Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study.

Authors: Timo R de Haan; Yuma A Bijleveld; Johanna H van der Lee; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Henrica L M van Straaten; Mirjam M van Weissenbruch; Jeroen R Vermeulen; Peter H Dijk; Jeroen Dudink; Monique Rijken; Arno van Heijst; Koen P Dijkman; Danilo Gavilanes; Anton H van Kaam; Martin Offringa; Ron A A Mathôt
Journal: BMC Pediatr Date: 2012-05-22 Impact factor: 2.125

20 in total

1. Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care.

Authors: Karel Allegaert; Catherine Sherwin
Journal: Eur J Pediatr Date: 2016-01-07 Impact factor: 3.183

2. Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life.

Authors: Stephanie Piekos; Chad Pope; Austin Ferrara; Xiao-Bo Zhong
Journal: Curr Pharmacol Rep Date: 2017-01-03

3. A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetamide: Lessons to Help Improve Future Product Development in Neonates.

Authors: Karel Allegaert; Amir Lahav; John N van den Anker
Journal: Paediatr Drugs Date: 2016-10 Impact factor: 3.022

Review 4. Design and conduct of early phase drug studies in children: challenges and opportunities.

Authors: Michael Rieder; Daniel Hawcutt
Journal: Br J Clin Pharmacol Date: 2016-08-08 Impact factor: 4.335

5. Substitution as a Strategy to Improve Excipient Exposure in Neonates: One Piece of the Puzzle.

Authors: Karel Allegaert; Isabel Spriet
Journal: Paediatr Drugs Date: 2016-06 Impact factor: 3.022

6. Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development.

Authors: Kay D Beharry; Charles L Cai; Gloria B Valencia; Douglas Lazzaro; Arwin M Valencia; Fabrizio Salomone; Jacob V Aranda
Journal: Prostaglandins Other Lipid Mediat Date: 2017-09-18 Impact factor: 3.072

7. Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations.

Authors: Tamara van Donge; Marc Pfister; Julia Bielicki; Chantal Csajka; Frederique Rodieux; John van den Anker; Aline Fuchs
Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191